Abcellera Biologics Net Income Over Time
| ABCL Stock | USD 3.86 0.04 1.03% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Abcellera Biologics Performance and Abcellera Biologics Correlation. Abcellera | Build AI portfolio with Abcellera Stock |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Abcellera Biologics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.459 | Earnings Share (0.57) | Revenue Per Share | Quarterly Revenue Growth 0.376 | Return On Assets |
Understanding Abcellera Biologics requires distinguishing between market price and book value, where the latter reflects Abcellera's accounting equity. The concept of intrinsic value—what Abcellera Biologics' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Abcellera Biologics' price substantially above or below its fundamental value.
Understanding that Abcellera Biologics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Abcellera Biologics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Abcellera Biologics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Abcellera Biologics and related stocks such as Celldex Therapeutics, Vera Therapeutics, and Janux Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CLDX | (1.7 M) | (44.8 M) | (59.1 M) | (81.5 M) | (118.1 M) | (127.2 M) | (128.5 M) | (93 M) | (151.2 M) | (50.9 M) | (59.8 M) | (70.5 M) | (112.3 M) | (141.4 M) | (157.9 M) | (142.1 M) | (135 M) |
| VERA | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (53.4 M) | (32.6 M) | (89.1 M) | (96 M) | (152.1 M) | (136.9 M) | (130.1 M) |
| JANX | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (6.8 M) | (32.6 M) | (54.2 M) | (58.3 M) | (69 M) | (62.1 M) | (59 M) |
| SYRE | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (11.3 M) | (21.7 M) | (27.2 M) | (44.3 M) | (78.3 M) | (80.9 M) | (65.8 M) | (83.8 M) | (338.8 M) | (208 M) | (187.2 M) | (177.9 M) |
| BHVN | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (118.7 M) | (213.8 M) | (570.3 M) | (408.2 M) | (846.4 M) | (761.8 M) | (723.7 M) |
| SION | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (47.3 M) | (61.7 M) | (55.5 M) | (58.3 M) |
| IMNM | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (10.6 M) | (17.1 M) | (24.7 M) | (36.9 M) | (106.8 M) | (293 M) | (263.7 M) | (250.5 M) |
| PHVS | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (9 M) | (29.6 M) | (42.7 M) | (76.3 M) | (100.9 M) | (134.2 M) | (120.8 M) | (114.8 M) |
| XERS | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (26.6 M) | (60.1 M) | (125.6 M) | (125.6 M) | (122.7 M) | (94.7 M) | (62.3 M) | (54.8 M) | (49.4 M) | (51.8 M) |
| NUVB | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (33.6 M) | (41.7 M) | (86.8 M) | (104.2 M) | (75.8 M) | (567.9 M) | (511.1 M) | (485.6 M) |
Abcellera Biologics and related stocks such as Celldex Therapeutics, Vera Therapeutics, and Janux Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Abcellera Biologics financial statement analysis. It represents the amount of money remaining after all of Abcellera Biologics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Abcellera Biologics | ABCL |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 150 West 4th |
| Exchange | NASDAQ Exchange |
USD 3.86
Check out Abcellera Biologics Performance and Abcellera Biologics Correlation. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Abcellera Biologics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.